New investigational drug PTT-121: a first step toward future therapies?
NCT ID NCT07768176
First seen Aug 17, 2026 · Last updated Aug 17, 2026
Summary
This early-stage trial is testing an investigational drug called PTT-121 in healthy Chinese adults. The main goal is to see if the drug is safe and tolerable when given intravenously, and to understand how the body processes it. Participants will receive either the drug or a placebo, and researchers will monitor for any side effects and measure drug levels in the blood over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- PTT-121, an investigational drug given intravenously
- What this could lead to
- If successful, this early trial could pave the way for further studies of PTT-121 as a potential treatment for various conditions.
- What could go wrong
- This is a very early Phase 1 study focused on safety, not effectiveness. The drug may cause side effects or fail to show promise in later trials.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLLUNTEER are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking University Third Hospital
Beijing, Beijing Municipality, 100089, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.